– The 11th drug substance facility is released for cGMP operation in the WuXi Biologics’ global manufacturing network. This new facility enhances the company’s capability of providing commercial manufacturing at 4,000L to 20,000L scale, facilitating any project initiation within four…
Related Posts
A Transformation by the Numbers: Consumers Energy Provides Over 2,000 Incentives for Electric Vehicle Charging
JACKSON, Mich., July 18, 2022 /PRNewswire/ — Consumers Energy continues to power Michigan’s electric vehicle transformation, announcing today that it…
Metal 3D Printing Technology Landscape – IDTechEx Outline The Trends and the Whitespaces
BOSTON, June 2, 2022 /PRNewswire/ — Perfectly imperfect – that is the technology landscape in metal 3D printing boiled down.…
Algae Market is estimated to Rise at a CAGR of 10.9% during the Forecast Period, notes TMR Study
Algae biofuel’s rapid manufacturing and high energy content have contributed to its growing popularity Substantial sum of investment is being…